Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sgm-101
- Development stage
- Phase 3
- Lead developer
- Surgimab
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SGM-101 is a tumor-specific antibody conjugated to a near-infrared fluorochrome (BM104), designed for intraoperative fluorescence imaging of cancer. It selectively binds to carcinoembryonic antigen (CEA), which is overexpressed in many gastrointestinal and other tumors, enabling surgeons to visualize tumor margins and detect cancerous lesions during surgery. The agent is administered intravenously, typically four days before surgery, and has demonstrated safety and efficacy in clinical trials for colorectal cancer. SGM-101 was developed by SurgiMab in collaboration with Institut du Cancer de Montpellier - Val d'Aurelle and Leiden University Medical Center.
- Other names
- BM104-labeled anti-CEA mAbBM-104-labeled anti-CEA mAbBM 104-labeled anti-CEA mAbfluorochrome-labeled anti-CEA monoclonal antibody
Beyond the preview
Go deeper on sgm-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sgm-101.